Growth Metrics

Evolent Health (EVH) EBIT Margin (2016 - 2026)

Evolent Health has reported EBIT Margin over the past 11 years, most recently at 87.1% for Q4 2025.

  • For Q4 2025, EBIT Margin fell 8422.0% year-over-year to 87.1%; the TTM value through Dec 2025 reached 21.86%, down 2027.0%, while the annual FY2025 figure was 21.86%, 2027.0% down from the prior year.
  • EBIT Margin for Q4 2025 was 87.1% at Evolent Health, down from 0.18% in the prior quarter.
  • Over five years, EBIT Margin peaked at 3.67% in Q3 2022 and troughed at 87.1% in Q4 2025.
  • A 5-year average of 6.31% and a median of 2.52% in 2023 define the central range for EBIT Margin.
  • Biggest five-year swings in EBIT Margin: surged 10047bps in 2021 and later crashed -8422bps in 2025.
  • Year by year, EBIT Margin stood at 4.92% in 2021, then skyrocketed by 90bps to 0.49% in 2022, then tumbled by -682bps to 3.84% in 2023, then rose by 25bps to 2.88% in 2024, then plummeted by -2928bps to 87.1% in 2025.
  • Business Quant data shows EBIT Margin for EVH at 87.1% in Q4 2025, 0.18% in Q3 2025, and 0.26% in Q2 2025.